NeuroPace Inc — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
NeuroPace revised its non-employee director compensation policy effective May 28, 2026. Annual board retainer remains $45,000; committee chairs receive $10,000–$20,000 annually; initial equity grant set at $245,000 (65% options, 35% RSUs, vesting monthly over 3 years); annual equity grant of $130,000 (same structure, 1-year vesting). Directors may elect stock in lieu of cash. No specific changes from prior version are disclosed in the text.
Why this rating
Routine director compensation disclosure. Annual equity grants (~$130K per director) immaterial relative to $306M market cap. Standard administrative update.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.